Using molecular profiling to guide treatment for rare cancers
Official title: NCT MASTER Plattform Molecularly Aided Stratification for Tumor Eradication Research
Run by German Cancer Research Center · NCT05852522 · Data updated 2026-11-12
This study is trying to see if using detailed genetic information can help doctors choose better treatments for adults with rare cancers that don’t have standard options.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 10000 (estimated) |
| Sponsor | German Cancer Research Center Academic / other |
| Locations | 1 site (Heidelberg) |
| Status | Recruiting |
| Started | November 11, 2018 |
| Main results expected | October 2028 |
| Study ends | October 2029 |
| Registry record updated | March 4, 2025 |
| Trial ID | NCT05852522 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults diagnosed with rare cancers or rare subtypes of more common cancers that are metastatic or locally advanced and have no curative therapy available.
✕Probably not a fit
Patients with severe neurological or psychiatric disorders that prevent them from providing informed consent may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to improve treatment strategies for adults with rare cancers by utilizing comprehensive molecular profiling. Participants will be stratified based on their unique tumor biology, and treatment decisions will be made in a multidisciplinary molecular tumor board setting. The study continuously recruits patients with metastatic or locally advanced rare cancers that lack curative therapy options. By focusing on rare cancer types, the study seeks to enhance personalized medicine approaches in oncology.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and tailored treatment options for patients with rare cancers.
How similar studies have gone: Other studies utilizing molecular profiling for cancer treatment have shown promising results, indicating that this approach is both relevant and potentially effective.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Rare cancer (Incidence \<6/100,000 persons/year) or Rare subtype of a more common entity (case-by-case decision; example: pancreatic ductal adenocarcinoma without KRAS mutation) Metastatic and/or locally advanced cancer with no curative therapy option and indication for systemic therapy Exclusion Criteria: Severe neurological or psychiatric disorder interfering with the ability to give oral and written informed consent
Where it's running
-
German Cancer Research Center
Heidelberg, Germany Recruiting
Study contacts
- Principal investigator: Stefan Fröhling, M.D. — German Cancer Research Center
- Study coordinator: Richard F Schlenk, M.D.
- Email: richard.schlenk@nct-heidelberg.de
- Phone: +49 6221
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding post‑cardiac arrest brain injury through spinal fluid molecular analysis
This project will test whether detailed molecular analysis of spinal fluid from people who had a cardiac arrest can reveal targets for new treatments.
-
AI system for diagnosing and predicting outcomes of breast phyllodes tumors
This study is testing whether an AI system can help doctors better diagnose and predict outcomes for patients with rare breast phyllodes tumors.
-
Targeting rare cancers with genomic therapy
This study is testing if personalized treatments based on the genetic makeup of rare tumors can help patients feel better and improve their outcomes.
-
Access to continued treatment with dabrafenib and/or trametinib for eligible patients
This study is for patients with melanoma, lung cancer, or other solid tumors who have been doing well on dabrafenib and/or trametinib and want to keep getting these treatments without a break.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.